LOADING

Type to search

Chinese COVID-19 Vaccine Shows 50.4 Percent Efficacy in Brazil Trial

Americas Brazil CCP Virus China Chinese Regime Chinese vaccine CoronaVac International PUBLIC HEALTH INFORMATION Sinovac World

Chinese COVID-19 Vaccine Shows 50.4 Percent Efficacy in Brazil Trial

Share

A leading Chinese COVID-19 vaccine candidate has been found to be 50.4 percent effective, according to the results of a late-stage trial in Brazil, a potential setback to the Chinese regime as it seeks to leverage the vaccine to boost its global image. The results from Brazil’s state-funded Butantan Institute on Jan. 12 were just enough to pass the 50 percent threshold set by the World Health Organization for regulatory approval. It was far lower than initial claims announced last week that touted a 78 percent efficacy rate. CoronaVac, a vaccine developed by Beijing-based drugmaker Sinovac Biotech, is one of Brazil’s two immunization candidates. The government last week made a deal to purchase up to 100 million doses of the Chinese vaccine. The latest revelation has fueled skepticism about Chinese vaccines. Brazilian President Jair Bolsonaro, who in October vowed that “Brazilian people will not be anyone’s guinea pig,” said on …

Leave a Comment

Your email address will not be published. Required fields are marked *